<HashMap><database>GEO</database><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311975</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Regulation of lineage reprogramming by dynamic chromatin SUMOylation (RNA-seq)</name><description>SUMOylation has emerged as a key regulator of chromatin and transcription, yet its contribution to lineage reprogramming remains unclear. To explore how chromatin SUMOylation influences cellular plasticity, we studied CEBPA-driven lineage reprogramming of human leukemic B-cells into macrophage-like cells. By integrating ChIP-seq, ATAC-seq, RNA-seq and chromatin-directed proteomics, we mapped the chromatin landscape and transcriptomic changes during early reprogramming. Lineage conversion triggered a dynamic rise in SUMO2/3 chromatin occupancy at CEBPA-bound sites, revealing a coordinated regulatory mechanism. Proteomic profiling of SUMO2/3- and CEBPA-associated chromatin uncovered extensive convergence and enrichment of differentiation-related transcription factors, chromatin remodelers and coregulators. Among these, NCOA3 displayed markedly increased SUMO2/3 association upon lineage conversion. NCOA3 co-occupied CEBPA- and SUMO2/3-bound chromatin regions, implying a SUMOylation-supported coregulatory role in lineage reprogramming. Pharmacological inhibition of SUMOylation using ML-792 (SUMOi) selectively enhanced CEBPA chromatin occupancy and chromatin accessibility, altered the CEBPA association of proteins, and modified NCOA3 binding dynamics. SUMOi also reshaped gene expression, promoting loss of B-cell identity and activation of macrophage-associated programs, including lipid metabolism. Collectively, our findings highlight chromatin SUMOylation as a dynamic and context-dependent modifier that fine-tunes lineage transitions, with implications for chromatin biology and therapeutic modulation of cell identity.</description><dates><publication>2026/05/27</publication></dates><accession>GSE311975</accession><cross_references><GSM>GSM9335469</GSM><GSM>GSM9335502</GSM><GSM>GSM9335503</GSM><GSM>GSM9335500</GSM><GSM>GSM9335489</GSM><GSM>GSM9335467</GSM><GSM>GSM9335501</GSM><GSM>GSM9335468</GSM><GSM>GSM9335504</GSM><GSM>GSM9335505</GSM><GSM>GSM9335483</GSM><GSM>GSM9335484</GSM><GSM>GSM9335481</GSM><GSM>GSM9335482</GSM><GSM>GSM9335487</GSM><GSM>GSM9335465</GSM><GSM>GSM9335466</GSM><GSM>GSM9335488</GSM><GSM>GSM9335485</GSM><GSM>GSM9335486</GSM><GSM>GSM9335464</GSM><GSM>GSM9335480</GSM><GSM>GSM9335478</GSM><GSM>GSM9335479</GSM><GSM>GSM9335494</GSM><GSM>GSM9335472</GSM><GSM>GSM9335495</GSM><GSM>GSM9335473</GSM><GSM>GSM9335492</GSM><GSM>GSM9335470</GSM><GSM>GSM9335471</GSM><GSM>GSM9335493</GSM><GSM>GSM9335498</GSM><GSM>GSM9335476</GSM><GSM>GSM9335477</GSM><GSM>GSM9335499</GSM><GSM>GSM9335474</GSM><GSM>GSM9335496</GSM><GSM>GSM9335497</GSM><GSM>GSM9335475</GSM><GSM>GSM9335490</GSM><GSM>GSM9335491</GSM><GPL>11154</GPL><GSE>311975</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>